This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Cytovac A/s. Active years: 2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2018
Title: Karine Dzhandzhugazyan: Innovator in Anti-Tumor Vaccine Development
Introduction
Karine Dzhandzhugazyan is a prominent inventor based in Copenhagen, Denmark. She has made significant contributions to the field of immunology, particularly in the development of anti-tumor vaccines. Her innovative approach focuses on utilizing normal cells to induce immune responses against tumors.
Latest Patents
Karine holds a patent for an anti-tumor vaccine derived from normal cells. This composition is designed to induce an immune response in mammals and comprises lymphoid cells in which the expression of tumor antigens has been chemically induced. The tumor antigens are induced in proliferating normal lymphoid cells, especially during the log phase of proliferation. The proliferation of these normal lymphoid cells is stimulated by normal mature dendritic cells. The lymphoid cells are primarily lymphocytes, particularly peripheral blood lymphocytes. The tumor antigens typically include cancer/testis antigens, which can be chemically induced by DNA demethylation. This innovative composition is capable of raising an immune response effective against a wide range of tumors, despite being derived from normal cells. It may be utilized for the preparation of an anti-tumor vaccine for both prophylactic and therapeutic use. Additionally, the composition can be employed for ex vivo activation of cytotoxic T lymphocytes, followed by their expansion through normal dendritic cells, facilitating cancer treatment via adoptive T cell immunotherapy.
Career Highlights
Karine Dzhandzhugazyan has established herself as a key figure in her field through her groundbreaking research and patent contributions. She is currently associated with Cytovac A/S, where she continues to advance her work in immunotherapy and vaccine development.
Collaborations
Karine collaborates with Alexei Kirkin, contributing to the innovative research and development efforts at Cytovac A/S.
Conclusion
Karine Dzhandzhugazyan's work in developing an anti-tumor vaccine represents a significant advancement in cancer treatment. Her innovative approach and dedication to research continue to inspire progress in the field of immunology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile